학술논문
A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease
Document Type
Article
Author
Source
In Respiratory Medicine May 2015 109(5):606-615
Subject
Language
ISSN
0954-6111